Drug Trial Radar · NCT01562834
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Oct 21, 1998
Primary completion
Dec 1, 2002
Study completion Dec 1, 2002
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.
Conditions
- Growth Hormone Disorder
- Adult Growth Hormone Deficiency
Interventions
somatropinDrug
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
placeboDrug
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Left ventricular mass measured with ultrasonography
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Angers, France
Novo Nordisk Investigational Site
Boisguillaume, France
Novo Nordisk Investigational Site
Brest, France
Novo Nordisk Investigational Site
Caen, France
Novo Nordisk Investigational Site
Grenoble, France
Novo Nordisk Investigational Site
Le Kremlin-Bicêtre, France
Novo Nordisk Investigational Site
Lille, France
Novo Nordisk Investigational Site
Lorient, France
Novo Nordisk Investigational Site
Lyon, France
Novo Nordisk Investigational Site
Lyon, France
Novo Nordisk Investigational Site
Marseille Cédex 05, France
Novo Nordisk Investigational Site
Montpellier, France
Novo Nordisk Investigational Site
Nantes, France
Novo Nordisk Investigational Site
Nantes, France
Novo Nordisk Investigational Site
Nice, France
Novo Nordisk Investigational Site
Paris, France
Novo Nordisk Investigational Site
Paris, France
Novo Nordisk Investigational Site
Paris, France
Novo Nordisk Investigational Site
Reims, France
Novo Nordisk Investigational Site
Rennes, France
Novo Nordisk Investigational Site
Strasbourg, France
Novo Nordisk Investigational Site
Toulouse, France
Novo Nordisk Investigational Site
Tours, France
Novo Nordisk Investigational Site
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.